WASHINGTON — The House Ways and Means Committee is poised to vote on a slate of as-yet-unintroduced drug pricing bills that would require sweeping disclosures from both drug middlemen and drug makers, according to summaries of the legislation obtained by STAT.

The committee’s markup, which lobbyists say will be held Tuesday, will follow a flurry of drug pricing action on Capitol Hill in recent days. House Democrats, in particular, appear to be moving toward legislating in earnest on the issue, although which bills will ultimately be signed into law, or the strategy for getting them to the president’s desk, is still unclear.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • The PBM Accountability Act, would require pharmacy middlemen to report their “aggregate rebates, discounts, and other price concessions” to a public website. WOW !!!! Can you Imagine ? Well IT’S ABOUT FU_ _IN TIME!! But , I’ll believe it when I see it !!!
    Yet the PBM’s complained that publicizing their rebates to competitors and drug makers would only make it harder for them to negotiate down the price of drugs. What a set of baseballs they have ! What they meant to say is ” How are we going to steal all those Billions of dollars we’ve
    been doing for so many years ” I guess being transparent makes it harder to negotiate prices. PBM’s must think we’re stupid. Thing are much easier when the PBM’s clients don’t know how much they pay the pharmacies.

Your daily dose of news in health and medicine

Privacy Policy